Autopsy report · NCT01207765
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Cause of deathOther
“changes in practice”
Life of this trial
- Registered 2 years 5 months after it had already started.
- Ran for about 5 years 2 months before it stopped.
- 8 participants enrolled.
- Results were posted on the registry 3 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Tufts Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Multiple Myeloma
- Interventions
- indium-111-ibritumomab tiuxetan; 90Y Zevalin
- Participants
- 8
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.